RxDoctor Payments Data

Daniel Graf, MD

Neurology · Norfolk, VANPI 1255591434

Payments from drug & device makers

$12,830in general payments, 2019–2025

Across 54 payments — averaging $237.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$8K
  • Livanova USA, Inc.$2K
  • SK Life Science, Inc.$582
  • Neurelis, Inc.$489
  • Eisai Inc.$447
  • Neuropace, Inc.$300
  • plus $545 from 6 others

What the payments were for

  • Consulting fees$6755%
  • Speaking & faculty fees$6,30049%
  • Travel & lodging$9087%
  • Food & beverage$4,89738%
  • Education$510%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,830 in reported general payments places this provider in the 70th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$54,520
Medicare patients
507
Services billed
649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam66$105,112
EpidiolexCannabidiol (Cbd)12$82,581
XcopriCenobamate26$27,766
NayzilamMidazolam30$26,987
AptiomEslicarbazepine Acetate18$24,889
Nurtec OdtRimegepant Sulfate13$24,818
Clobazam67$22,882
Lacosamide189$21,896
FycompaPerampanel16$18,571
ValtocoDiazepam16$12,384
Levetiracetam441$11,335
Oxcarbazepine58$6,367
Zonisamide73$3,803
Divalproex Sodium ErDivalproex Sodium71$2,813
Divalproex Sodium45$2,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$8,337$132,09996 claims
SK Life Science, Inc.Xcopri$582$27,76626 claims
Sunovion Pharmaceuticals Inc.Aptiom$99$24,88918 claims
Eisai Inc.Fycompa$447$18,57116 claims
Neurelis, Inc.Valtoco$489$12,38416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 neurology providers in Virginia.

Other neurology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →